Researchers say that people who get plenty of the sunshine Vitamin D may end up preventing certain diseases.

Having more of the vitamin that serves as the principal regulator of calcium in the body, may also protect against specific autoimmune disorders including multiple sclerosis (MS) according to Sylvia Christakos, PhD, of the UMDNJ-New Jersey Medical School

The Philadelphia VA Medical Center is investigating its treatment of 114 cancer patients on suspicion they might have received the wrong radiation doses.

The hospital admitted its error Tuesday, saying it's reviewing records of prostate-cancer patients who underwent brachytherapy during the past six years. The men may have received radiation dosages below the recommended levels. The treatment involved implanting radioactive rods or seeds in and around the prostate to destroy cancer cells in men who have low-risk prostate cancer

A U.S. panel that studies the effectiveness of clinical preventive services and medications has recommended that men aged 75 and above avoid prostate cancer screening because it offers few benefits and more harm.

According to the recommendation of the U.S. Preventive Services Task Force appearing in Tuesday's issue of the Annals of Internal Medicine, the panel found evidence that prostate cancers detected through the prostate-specific antigen (PSA) test take more than 10 years, the life expectancy of men over 75, to become life-threatening

An independent panel of experts Monday recommended against prostate cancer screenings for men older than 74 due to more evidence of harm than benefit.

The U.S. Preventive Services Task Force (USPSTF), updating its 2002 report, added that more evidence is needed to determine if men under 75 could benefit from screening

Australian researchers have found that combining three new prostate drugs in treating advance prostate cancer is more effective and causes fewer side effects for patients.

Dr. Wayne Tilley and Dr. Lisa Butler of the University of Adelaide's Dame Roma Mitchell Cancer Research Laboratories have successfully killed prostate cancer cells in laboratory studies using low doses of bicalutamide in combination with the anti-cancer drugs 17AAG or vorinostat. The method inhibits prostate cancer cell proliferation more than tenfold, according to the researchers